An exclusive distribution co-operation was signed by Egis Pharmaceuticals Zrt Mundipharma network is a bio-like product with pegfilgrastim marketing. Under the contract, Egis has acquired the exclusive right to chemotherapy side effects, the duration of neutropenia and fever the market to reduce the incidence of neutropenia. For the company with this it is possible to introduce this new bio-like product in four Eastern European countries. Neutropenia, a common side effect of chemotherapy, means that a The number of white blood cells, neutrophils, falls critically low, thus the risk of life-threatening infections increases with the affected patients. Pegfilgrastim a bio-like preparation to reduce the duration of neutropenia and febrile neutropenia used to prevent it. The product was authorized by the European Union in November 2018 Medicines Agency (EMA). The bio-like product of pegfilgrastim is subcutaneously administered to be given. As a result of the strategic agreement, it will be available in four of the Egis markets pegfilgrastim therapy: the company acquired the Hungarian, Romanian, Lithuanian and Latvian markets exclusive distribution of the product. ?Egis is now introducing its fourth biosimilar medicine in Central and Eastern Europe. We are committed to making the widest possible range of patients available our leading therapeutic solutions, with more affordable prices in Central and Eastern Europe and CIS countries. Our agreement with Mundipharma further strengthens , ?said dr. Istv?n Hod?sz, CEO of Egis. ?We are pleased to have a partnership with Egis in Central and Eastern Europe this biosimilar drug that is part of the drug chain is available. Long-term through our cooperation, it is possible to reduce health in this region spending so that patients can access it more easily at the same time Effective Therapy ?, added Alberto Martinez, Mundipharma's European CEO. Egis is an important player in the market for biopharmaceuticals: the first biosimilar monoclonal antibody (mAb) was released on the European Union market in 2013. A bio-like mAb In the field of pharmaceuticals, the company played a pioneering role in the autoimmune disease suffer from cost-effective treatments. After that, Egis has two more bio-related to oncology and oncohematology - autoimmune disease has appeared in 15 countries of Central and Eastern Europe and CIS. With the current agreement, the company took another step towards its strategic goals: to strengthen its presence in the bio-like products market, improving patient access to cutting-edge therapeutic options at affordable prices in Central and Eastern Europe and CIS countries. Pegfilgrastim is a bio-like With this product, Egis is expanding its oncohematology portfolio - a strategic goal. More information: Mariann Menthy menthy.mariann@egis.hu About Egis: The Budapest based Egis Pharmaceuticals Ltd. is Hungary and the Central and Eastern European region one of the leading generic pharmaceutical factories, its field of activity is the pharmaceutical value chain complete covers the spectrum of research and development through active ingredients and finished products a marketing, sales. Egis products - from active ingredients to tablets, injections to galenic preparations - besides Hungary, in 70 countries worldwide available through subsidiaries or representations. It sells its products in 18 countries Egis brand name. Egis Pharmaceuticals Ltd. - controlled by a nonprofit foundation in France is a member of the international pharmaceutical company Servier group - more than four thousand employs employees in Hungary and abroad. In the financial year 2017/18, the net sales of the Egis Group were HUF 157 billion. For more information: https://hu.egis.health/